Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  H. Lundbeck A/S    LUN   DK0010287234

H. LUNDBECK A/S (LUN)

32
SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo H. Lundbeck A/S
Engages in research, development, production, marketing and sale of pharmaceuticals for the treatment of diseases of the central nervous system

Lundbeck H AS is engaged in the research, development, manufacture and distribution of pharmaceuticals for brain disorders.

It focuses on the treatment of brain disorders such as Alzheimer's disease, epilepsy, Huntington's disease, mood disorders, Parkinson's disease, and psychosis.

The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

Number of employees : 5 518 persons.
Sales per Businesses
20122013Delta
DKK (in Million)%DKK (in Million)%
Cipralex5,82739.4%5,93338.9% +1.79%
Ebixa2,80318.9%2,09613.7% -33.73%
Other Pharmaceuticals2,17414.7%1,83012% -18.8%
Azilect1,2248.3%1,3929.1% +12.07%
Xenazine1,1978.1%1,4209.3% +15.7%
Other626.004.2%1,4849.7% +57.82%
Lexapro575.003.9%---
Sabril376.002.5%530.003.5% +29.06%
Onfi--573.003.8%-
Sales per Regions
20122013Delta
DKK (in Million)%DKK (in Million)%
Rest of Europe7,68751.9%7,02846.1% -9.38%
Rest of the World3,76825.5%4,07526.7% +7.53%
United States2,67418.1%2,63517.3% -1.48%
Denmark47.000.3%36.000.2% -30.56%
Managers
NameAgeSinceTitle
Ulf Arne Wiinberg562008President & Chief Executive Officer
Sven Håkan Björklund MD, PhD582011Chairman
Lars Bang521988SVP-Supply Operations & Engineering
Ole Chrintz--SVP-Commercial Operations & International Markets
Anders Götzsche472007Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen MD, PhD632000Executive Vice President-Research & Development
Thorleif Krarup622004Director
Jes Christian Wibroe Østergaard662003Director
Jørn Møller Mayntzhusen, MBA482002Director & Senior Manager-Supply Optimisation
Kim Rosenville Christensen551993Director & Synthesis Operator
Shareholders
NameShares%
Lundbeck Foundation 137,351,91869.9%
Wellington Management Co. LLP 3,168,9361.61%
Norges Bank Investment Management 2,570,2881.31%
OppenheimerFunds, Inc. 2,400,0001.22%
Templeton Global Advisors Ltd. 1,716,2270.87%
M&G Investment Management Ltd. 1,583,0890.81%
Franklin Templeton Investment Management Ltd. 1,365,1700.70%
TIAA-CREF Investment Management LLC 680,0000.35%
The Vanguard Group, Inc. 597,8510.30%
Amundi SA (Investment Management) 561,5770.29%
Holdings
NameShares%Valuation
Biotie Therapies Oyj (BTH1V) 18,604,6514.08%4,923,349 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
ROCHE HOLDING LTD..
NOVARTIS AG
PFIZER INC.
MERCK & CO., INC.
SANOFI
BAYER AG
GLAXOSMITHKLINE P..
NOVO NORDISK A/S
BRISTOL-MYERS SQU..
ELI LILLY AND CO
ABBOTT LABORATORI..
ACTAVIS PLC
SHIRE PLC
ALLERGAN, INC.
TEVA PHARMACEUTIC..
VALEANT PHARMACEU..
REGENERON PHARMAC..
TAKEDA PHARMACEUT..
ASTELLAS PHARMA I..
Sector Pharmaceuticals
Company contact information
9 Ottiliavej
DK 2500 Valby, Copenhagen
Denmark

Phone : +45 36 30 13 11
Fax : +45 36 30 19 40
Internet : http://www.lundbeck.com
Markets and indexes
- NASDAQ OMX nordic Kopenhagen
- Main Market Large
Stock Exchange Codes
- ISIN Code :  DK0010287234
- Bloomberg Code :  LUN:DC
- Reuters Code :  LUN.CO
- Datastream Code :  DK:LUND
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF